Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafor in the Lenalidomide Era

Transplantation and Cellular Therapy(2021)10.1016/j.jtct.2021.04.016Source: DataRank Database

Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafor in the Lenalidomide Era is a research paper published in Transplantation and Cellular Therapy (2021). On theSindex it has a DataRank of 0. It has been cited 23 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access23 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 1.97)OA: greenTopics (33)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (17)

Abdullah Ladha ORCID,Lori Muffly ORCID,Parveen Shiraz ORCID,Gary Goldstein ORCID,Victoria Osgood

Live enrichment

PubMed:33915323 PMC:PMC8378276 OpenAlex:https://openalex.org/W3158117508

NCATS NIH HHS

Grant: KL2 TR003143

National Institutes of Health

FWCI

1.97

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

2026

greenLicense: http://creativecommons.org/licenses/by-nc-nd/4.0/

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8378276

publisherhttps://api.elsevier.com/content/article/PII:S2666636721008630?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2666636721008630?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jtct.2021.04.016

Fields of Study

Multiple Myeloma Research and TreatmentsHematopoietic Stem Cell TransplantationImmunotherapy and Immune Responses

MeSH Terms

LenalidomideCyclamsBenzylaminesCyclophosphamideHeterocyclic CompoundsHumansMultiple MyelomaRetrospective StudiesGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell TransplantationAntigens, CD34Hematopoietic Stem Cell Mobilization

Keywords

PlerixaforMedicineLenalidomideMultiple myelomaGranulocyte colony-stimulating factorCyclophosphamideApheresisChemotherapySurgeryMobilizationUrologyInternal medicineOncologyGastroenterologyCXCR4PlateletStem Cell MobilizationAutologous Hematopoietic Cell Transplantation

Sustainable Development Goals

SDG 0: Good health and well-being

Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafor in the Lenalidomide Era

FAIR Checklist

Authors (17)

Funding (2 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)